MMoving Forward: Sparking Change in Multiple Myeloma

Published on: March 7, 2025

Scientific breakthroughs in multiple myeloma (MM) research are revolutionizing treatment options, resulting in extended lifespans for individuals with MM^1,2. Despite these advancements, significant challenges persist. The disease's nature involves recurrent phases of remission and relapse, necessitating numerous critical treatment decisions to be taken throughout the patient's journey³.

We are committed to transforming the treatment paradigm, alongside patient groups, nurses, doctors, payers, and policymakers. This is why we have launched MMoving Forward, a global initiative that unites MM experts around the world to create innovative solutions which improve patients’ experience and quality of life.

How We Drive Change

We are on a long-term mission to help extend lives, ease the burden of disease, and help restore hope to those impacted by rare and difficult-to-treat cancers. To that end, our R&D programs are working to address common challenges like relapse and drug resistance, for example, by activating the immune system to fight MM cells through novel mechanisms and technologies.

Fueled by our focus on patient-integrated innovation, we are striving to harness the power of novel delivery systems, including a subcutaneous administration method with a proprietary on-body delivery system, to potentially help ease the burden of treatment for patients and their care teams alike.

Cancer treatment is not a one-size-fits-all approach. This is why we are committed to advancing oncology innovation through an unwavering determination to help extend lives, ease the burden and help restore hope to those impacted by cancer. As we continuously seek opportunities to accelerate and extend our R&D programs, MMoving Forward allows us to create together with the MM community innovative solutions to transform care for patients - improving their experience and long-term quality of life.

Olivier Nataf

Global Head of Oncology

Innovation does not happen in isolation, which is why we continue to collaborate with leading cancer institutions and top experts across the industry. Within MMoving Forward, we are focusing our advocacy efforts on:

Patient unmet needs

Driving understanding of MM as a long-term chronic disease and advocating to better serve the unmet needs of patients.

Our Ongoing Advocacy Work

At Sanofi, as part of the MMoving Forward initiative, we are joining forces with the MM community to:

Map out the challenges and barriers faced by newly diagnosed multiple myeloma patients across the care pathway.

Explore the pivotal role that nurses play in enabling the care journey of MM patients and improving their experience in the healthcare system.

Both projects will produce advocacy tools that can be used by the MM community – from patients to healthcare professionals – to engage with policy- and decision-makers regarding solutions for improving the patient experience in the healthcare system, as well as overall quality of life.

The MMoving Forward Alliance

The MMoving Forward initiative prioritizes creation together with the MM community within the MMoving Forward Alliance, a multistakeholder platform that brings together key patient representatives, healthcare professionals, academia, and other experts in MM care.

Members of the Alliance include:

Yelak Biru

Yelak Biru is the President of the International Myeloma Foundation.

Sophie Castell

Dr. Sophie Castell is Chief Executive Officer (CEO) of Myeloma UK.

Katie Joyner

Katie Joyner is Co-Chief Executive Officer (Co-CEO) of Myeloma Patients Europe (MPE).

Diane Loening-Martens

Diane Loening-Martens is the current Vice President of Myeloma Patients Europe. Loening-Martens is also a trained nurse with a specialty in palliative care.

Stephanie Malartre

Stephanie Malartre is an advanced practice nurse with a specialty in onco-hematology at the Centre Léon Bérard Lyon in France.

Mohamad Mohty

Professor Mohamad Mohty is currently a Professor of Hematology and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris.

Phillipe Moreau

Dr. Philippe Moreau is a specialist in clinical hematology, heading the hematology department at the University Hospital of Nantes in France. He is also President of the International Myeloma Society.

Johan de Munter

Johan de Munter is a nurse in oncology-hematology. He is the past president of the European Oncology Nursing Society (EONS) and current board member of the nurse committee of the Belgian Hematology Society.

Pellegrino Musto

Musto is a specialist in hematology and medical oncology - heading the department of precision and regenerative medicine at the University of Bari.

Paula Rodriguez

Dr. Paula Rodriguez is a specialist in hematology and hemotherapy, coordinating the Central Unit for Clinical Trials at Navarra University.

Maite San Miguel

Maite San Miguel is a nurse and coordinator of hematology clinical trials at the Navarra University.

John Weinman

Professor John Weinman is currently a Professor of Psychology applied to Medicines at the Institute of Pharmaceutical Science & Institute of Psychiatry, Psychology and Neuroscience, of King’s College in London.

Guiding Principles of Our Collaboration

B Puertas, V González-Calle, E Sobejano-Fuertes, et al. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers (Basel). 2023 Mar 2;15(5):1558. doi: 10.3390/cancers15051558.
J-A Hernández-Rivas, R Ríos-Tamayo, C Encinas, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022 Jan 9;10(1):1. doi: 10.1186/s40364-021-00344-2.
U-H Mellqvist, H T Steinmetz, A Perrot, et al. Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel. s 2023 May;23(5):e240-e251.e12. doi: 10.1016/j.clml.2023.02.010.

MAT-GLB-2500114 I February 2025